Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Horizon Wins on Pennsaid 2% Patent; Loses on Ravicti Patent (2)

Oct. 10, 2019, 2:08 PMUpdated: Oct. 10, 2019, 7:53 PM

Horizon won an appeals court ruling that upheld one of its patents for the arthritis drug Pennsaid 2% but lost one of its patents on the urea treatment Ravicti.

  • In the first of two rulings issued Oct. 10, the U.S. Court of Appeals for the Federal Circuit rejected arguments by Teva’s Actavis unit that Horizon patent 9,066,913 didn’t cover a new idea
  • Teva had conceded infringement of the patent, which expires in 2027, leaving only the issue of validity at trial
  • Ruling means Teva can’t sell its generic version of the drug until 2027
  • Horizon sought to revive other ...